has function has role vaccinated in route immunizes against disease immunizes recipient leukemia Homo sapiens subcutaneous route therapeutic vaccine function peptide vaccine vaccine in clinical trial role peptide vaccine role leukemia cancer vaccine Bcr-Abl peptide vaccine 6372 25 Gene name: bcr-abl cancer vaccine NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C2205 Hayleigh Kahn Jie Zheng VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6372 NCT: https://clinicaltrials.gov/study/NCT00004052 A cancer vaccine consisting of the bcr-abl b3a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b3a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b3a2 fusion protein. The bcr-abl p210-b3a2 breakpoint-derived pentapeptide vaccine is used in combination with GM-CSF. The peptides may help the body build an effective immune response to kill cancer cells, and the GM-CSF may increase the number of immune cells found in bone marrow or peripheral blood. This combination is used to treat patients with Philadelphia chromosome-positive chronic myelogenous leukemia. It can also be used in combination with imatinib mesylate to decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease NCT: https://clinicaltrials.gov/study/NCT00455221 therapeutic cancer vaccine